Troy Cox - Sep 1, 2021 Form 4 Insider Report for SomaLogic, Inc. (SLGCW)

Role
Director
Signature
/s/ Brian Emes, Attorney-in-Fact for Troy Cox
Stock symbol
SLGCW
Transactions as of
Sep 1, 2021
Transactions value $
$500,000
Form type
4
Date filed
9/3/2021, 08:30 PM
Previous filing
May 7, 2021
Next filing
Dec 13, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLGCW Class A Common Stock Other $0 +25K $0.00 25K Sep 1, 2021 Direct F1
transaction SLGCW Class A Common Stock Award $500K +50K +200% $10.00 75K Sep 1, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLGCW Warrants to purchase Class A Common Stock (right to buy) Award +167K 167K Sep 1, 2021 Class A Common Stock 167K $11.50 Direct F2
transaction SLGCW Class B Common Stock Options Exercise $0 -25K -100% $0.00* 0 Sep 1, 2021 Class A Common Stock 25K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II Inc. or "CMLS II") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of CMLS II's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.
F2 Following the completion of the Business Combination, warrants to purchase Class A Common Stock become exercisable on October 1, 2021, the date that is 30 days after the closing of the Business Combination.